Thursday, December 30, 2010

Exercise/Pulmonary Rehab and COPD

Exercise/Pulmonary Rehab and the COPD patient


Patients with chronic obstructive pulmonary disease often report dyspnea (shortness of breath) on exertion and therefore over time tend to decrease their overall activity. Over time this limitation in activity causes an individual to get short of breath with less activity resulting in an individual becoming less active.

Activity is an important component of one’s everyday life; otherwise individuals will have more symptoms with less and less activity. However starting an exercise program is difficult, especially if one is short of breath with minimal activity as many individuals with chronic obstructive pulmonary disease are. Therefore, many individuals limit their activity because any sort of exertion or activity that increases shortness of breath makes them decrease their activity.

Many individuals with COPD are concerned about starting an exercise program and would benefit greatly from guidance from healthcare professionals. If an individual with COPD is apprehensive about exercise or has extremely limited exercise tolerance, they would benefit greatly from a referral to pulmonary rehabilitation.


see more exercise / COPD info at the lung health professional org

Sunday, December 26, 2010

portable lung machine / like the home dialysis machine by Baxter

portable aid machine / like the home dialysis machine by Baxter ?





Just found out today that a friend now has his own dialysis machine at
home, it seems the cost and designs have advanced in the last few years.

How, if this idea can be used for people with emphysema /copd ?
there is a large definite market out there for people suffering from COPD.
The market potential is probably greater than dialysis, I would guesstimate in the millions of potential customers.

Is a home lung machine next ?

A lung machine would concentrate the oxygen and remove the CO2,

about the home dialysis...
HomeChoice PRO™ Baxter Healthcare Corporation SPONSOR
http://www.baxter.com

Purpose: CCPD/APD
Size: 7h x 19.5w x 15.7d inches and 26.8 lbs.
Benefits: Automated dialysis overnight, easy to use, and accurate recording
Special Features: Transfer therapy data from home to dialysis center and vice versa.

Anti-Smoking Campaign: Tar

Anti-Smoking Campaign: Tar




Anti-Smoking Campaign: Tar

Gas Exchange

Gas Exchange within the lung

Gas exchange within your lungs

Short video on how Gas exchanges within your lungs

Respiratory System, Breathing, Lungs

Respiratory System, Breathing, Lungs



Oxygen transport within your body

Oxygen transport within your body


picture of damaged alveoli

picture of damaged alveoli

Friday, December 24, 2010

Photo of a ALung / HemoLung

Pete DeComo, chief executive officer, and Nick Kuhn, chief operating officer of ALung, show off their HemoLung respiratory-assist device that works as an artificial lung for medical patients.


see more info at
http://www.post-gazette.com/pg/10005/1025746-114.stm?cmpid=news.xml#ixzz195CbJVwV

Slide show on the Hemolung br DR Tushar M Chokshi



artificial lung,copd,DR Tushar M Chokshi,hemolung

Pulmonary Reviews is a monthly news magazine

About Pulmonary Reviews

Pulmonary Reviews is a monthly news magazine for physicians who specialize in pulmonary and/or critical care medicine. It provides physicians with information on disorders that affect the lungs and respiratory tract.

Articles cover such topics as asthma, ARDS, pneumonia, influenza, sepsis, emphysema, chronic bronchitis, sleep apnea, AIDS, and pulmonary embolic disease.

Reports on clinical research findings being presented at major American and international medical conferences (including the annual meetings of the American Thoracic Society, the American College of Chest Physicians, the American College of Allergy, Asthma, and Immunology, the Society of Critical Care Medicine, and the European Respiratory Society) as well as incisive reports on significant findings presented in the peer review literature are included in each issue.

Also included are a variety of departmental features, including News Roundup, Clinical Trial Update, New Products, and Literature Monitor.


see the website for Pulmonary Reviews

How about a partial fix/solution for severe COPD / emphysema

 
How about a partial fix/solution for severe COPD / emphysema....?
 
 
 
 
 
 
 


The problem is really 2 parts, O2 input is hindered and carbon dioxide output is limited. Oxygen therapy is a partial solution for the input side of this equation/problem. Has there been any research / thoughts on the 2nd part removing carbon dioxide?





Advanced lung disease is characterised by an inability to remove carbon dioxide from the blood and reduced oxygen uptake efficiency. A shortage of donors can mean long delays and high mortality rates for those awaiting a transplant. The only technology available to aid sufferers during this time is an external lung type of machine.

 

Tuesday, December 21, 2010

what is the National Lung Health Education Program ?

what is the National Lung Health Education Program ?


Who We Are —

The National Lung Health Education Program (NLHEP), was initiated in 1996 as a new healthcare initiative designed to increase awareness of Chronic Obstructive Pulmonary Disease (COPD) among the public and health care professionals and to encourage the use of simple spirometry to make an early diagnosis and monitor ongoing treatment.

The NLHEP initiative is directed to primary care physicians, other healthcare clinicians, government officials, policy makers, health care agencies and especially to patients. Many societies, including governmental agencies support NLHEP, and financial support for our organization comes from a wide range of sources, including unrestricted grants from other non-profit organizations, patient advocacy groups, private donors, along with unrestricted grants from the pharmaceutical and medical support industries.


click to see the offical website National Lung Health Education Program

Saturday, December 18, 2010

UK Lung organization in the UK

1 in 7 people in the UK have some sort of lung problem.
see the UK national website at http://www.lunguk.org/



http://lunguk.org/

Flu problems brewing in the UK

Dr Laurence Buckman, chairman of the British Medical Association's GP committee, has written to the Government urging it to step up its publicity campaign telling people at risk that the vaccine is safe and effective.
He said: 'Family doctors are already seeing high rates of influenza and they have been telling us that they are also seeing a lower uptake than usual for seasonal flu immunisation. 'Myths persist about the safety of the vaccine, especially after swine flu. 'The vaccine has been thoroughly tested and we strongly urge patients to make an appointment with their GP and get vaccinated.

'It is only the beginning of winter so we could see many more cases of flu for the next few months - the BMA strongly urges at-risk groups to get immunised, flu can be extremely serious.'
Overall, 17 people, including four pregnant women, with confirmed swine flu have received specialist intensive care treatment - known as extra corporeal membrane oxygenation (ECMO) - so far this flu season.  ECMO is a life support system for the most severe cases and uses an artificial lung to oxygenate the blood outside the body.
During the pandemic, pregnant women who caught swine flu were found to be more at risk of breathing problems than women who were not pregnant.  Louise Silverton, Deputy General Secretary of the Royal College of Midwives, added: 'Pregnant women should not panic, but we do advise them to have the vaccine and practise good hand hygiene to prevent the spread of germs.

see more info at....
UK GPs warn major flu crisis brewing

Read more: http://www.dailymail.co.uk/health/article-1339564/Pregnant-women-urged-flu-jab-GPs-warn-major-flu-crisis-brewing.html#ixzz18R60f6Mu

Friday, December 17, 2010

Lung Oxygen Measurement / artifical lung

Oxygen MeasurementMeasure Trace & Percent Oxygen Contact Alpha Omega Instrumentswww.aoi-corp.com
An artificial lung for humans and other mammals inserted within the body or placed externally. The artificial lung comprises an electrically actuated three-way valve, a casing containing parallel loops of oxygenator tubes for oxygenation of blood by an atmosphere of circulating air, and an air circulation driving fan powered by an energizing system. As a safety factor in the event of leakage in the casing, a check valve is inserted in an effluent blood duct from the casing to the aerated effluent blood. Two artificial lungs can be utilized internally as left and right lungs.

 
 
 
 
Artificial lung device  United States Patent 6723132
 
 
 
 

Thursday, December 16, 2010

ECMO used for infants



ECMO stands for Extra Corporeal Membrane Oxygenation. ECMO is used in infants who are extremely ill due to breathing or heart problems. The ECMO machine circulates blood through an artificial lung back into the bloodstream. This provides adequate oxygen to the baby while allowing time for the lungs and heart to "rest" or heal.

see source at...
http://www.edward.org/body.cfm?xyzpdqabc=0&id=223&action=detail&AEArticleID=19844&AEProductID=Adam2004_1&AEProjectTypeIDURL=APT_2

Wednesday, December 15, 2010

Lung implant is a breath of fresh air

Lung implant is a breath of fresh air December 2010







Artificial lung technology could reduce the death rate for patients awaiting a lung transplant, say US scientists.

Advanced lung disease is characterised by an inability to remove carbon dioxide from the blood and reduced oxygen uptake efficiency. A shortage of donors can mean long delays and high mortality rates for those awaiting a transplant. The only technology available to aid sufferers during this time is based in intensive care units, hindering quality of life.

Now, Joseph Vacanti and coworkers at Massachusetts General Hospital, Boston, have developed a device that achieves the CO2/O2 gas exchange that, when implanted in the body, could allow patients more freedom when awaiting a transplant. Their design is a microfluidic branched vascular network through which blood flows, separated from a gas-filled chamber by a silicone membrane less than 10um thick. The network is formed by casting polydimethylsiloxane, a biocompatible polymer, on a micro machined mould.

A device that achieves carbon dioxide/oxygen gas exchange could allow patients more freedom when awaiting a lung transplant

A major challenge faced by Vacanti's team was achieving a blood pressure within the device's channels similar to that in veins and arteries. They applied computational fluid dynamics to optimise the vascular network's structure to avoid clotting induced by excessive blood pressure. 'Fulfilment of these design criteria necessitated creating channels that had variable depth throughout the network and also had precise curvature,' says Vacanti's coworker, David Hoganson.

Vacanti's device could be scaled up for implantation. According to Hoganson, an implant-sized device could be fabricated by 'stacking the functional layers of the device to achieve the necessary surface area for gas exchange'.

Jaisree Moorthy, who specialises in using microfluidics in tissue engineering at the University of Pennsylvania, says that Vacanti's device provides a very elegant solution. Compared to existing devices, Moorthy comments that it 'is more efficient due to a thinner membrane, and mimics the biological CO2/O2 transfer rate'.

In the future, Vacanti hopes to develop the device further to incorporate engineered lung tissue.

Link to journal articleLung assist device technology with physiologic blood flow developed on a tissue engineered scaffold platform

David M. Hoganson, Howard I. Pryor II, Erik K. Bassett, Ira D. Spool and Joseph P. Vacanti, Lab Chip, 2011

DOI: 10.1039/c0lc00158a


Now, Joseph Vacanti and coworkers at Massachusetts General Hospital, Boston, have developed a device that achieves the CO2/O2 gas exchange that, when implanted in the body, could allow patients more freedom when awaiting a transplant.


ChemScience Volume 2010 12 lung implant breath fresh air click to see source

see more info on this lung implant method procedure

Tuesday, December 14, 2010

MORE COPD PATIENTS COULD BENEFIT FROM OXYGEN THERAPY

MORE COPD PATIENTS COULD BENEFIT FROM OXYGEN THERAPY

The website 6-minutes, a daily newsletter for Australian doctors, reports on a study that finds many patients ineligible for supplemental oxygen under current criteria could still benefit from oxygen therapy. They conclude that a single daytime measurement of oxygen in the blood may not be the best method of determining who could benefit from oxygen therapy. Researchers find a large number of people are okay during the day, but have oxygen saturations below 90 percent at night. For more information, see:

More COPD patients could benefit from oxygen

Many COPD patients with borderline hypoxaemia would benefit from long term oxygen therapy but are currently excluded due to misleading one-off measurements of oxygenation, Victorian researchers say.

A study of 35 COPD patients with moderate hypoxaemia on resting showed that 24-hour oximetry was able to identify a large subgroup of patients who had clinically significant hypoxaemia throughout the day and especially at night.

The use of ambulatory oximetry showed that 54% of patients spent more than 30% of the monitoring period with oxygen saturation below 90%, “suggesting a significant degree of hypoxaemia that is often missed by point measurement of PaO2,” say the researchers from Barwon Health in the Internal Medicine Journal (online 1 December) .

“We believe this group may include patients with the potential to benefit from this therapy [despite] being ineligible for prescription of long term oxygen therapy according to current criteria,” they write.

The study authors say long term oxygen therapy is known to improve survival, pulmonary dynamics and exercise capacity in patients with severe hypoxaemia, but currently eligibility for oxygen therapy is decided by point measurement of PaO2.

The study also showed that BMI was correlated with daytime hypoxaemia, whereas age and PaO2 were the only significant predictors of nocturnal hypoxaemia.

“Our findings suggest that a single daytime measurement of resting PaO2 may not be the optimal method for determining which patients will benefit from this approach to nocturnal oxygen prescription,” they say.

By Michael Woodhead

New lung disease network to benefit patients and boost UK economy

New lung disease network to benefit patients and boost UK economy



Scientists and clinicians in Nottingham are to work more closely with industry to develop new ways of diagnosing and treating lung disease.

Nottingham has been chosen as one of just nine centres across the UK to host a Government-spearheaded ‘Therapeutic Capability Cluster’, which aims to forge closer links between academia, the NHS and the life sciences industry to speed up the process of getting new drugs from lab bench to bedside.

The new cluster will draw on the world-leading research expertise of scientists at The University of Nottingham and clinical excellence of Nottingham University Hospitals NHS Trust to help pharmaceutical companies develop clinical trials for potential new treatments for a range of respiratory diseases.


see more at...
http://www.nottingham.ac.uk/news/pressreleases/2010/december/lungdiseasenetwork.aspx

Wednesday, December 8, 2010

U.S. servicemember survive having a lung removed downrange

Doctors say Griego — of Apache Troop, 1st Squadron, 75th Cavalry Regiment, 101st Airborne Division — is also the first U.S. servicemember in the Iraq and Afghanistan wars to survive having a lung removed downrange.

His journey back started with the brave actions of his fellow soldiers. Griego and his unit were securing a road in southern Afghanistan on Oct. 19 when Taliban fighters opened fire from a nearby building. Griego was shot in the chest, and blood spewed from a bullet wound under his right ribs. Sgt. Matt Casting and Sgt. Mark Reed stanched it, keeping Griego from hemorrhaging, the most common cause of combat death.

Then, amid the heated firefight, the unit’s medic, Spc. Allan Hughes, ran 650 meters to reach Griego, who was laboring to breathe because air was building in his lung cavity, putting pressure on his lungs to the point of near collapse. Hughes thrust a thick, long needle into Griego’s chest, relieving the pressure and saving his life yet again.

Advertisement
Minutes later, Griego was evacuated to the Role 3 hospital in Kandahar. There doctors discovered a tiny wound near the left side of Griego’s neck. This told them that the bullet had torn through his chest cavity, likely injuring both lungs, said U.S. Navy Dr. (Cmdr.) Eric Elster, director of surgical services at the hospital.

They wheeled Griego into the operating room. Elster and a team of surgeons searched for the severed vessels that poured blood into Griego’s lungs. They stapled off the top of Griego’s left lung, stemming the bleeding there.

But his right lung was full of holes. Despite their best efforts to stop all the leaks, the doctors could not control the bleeding, Elster said. So the surgeons clamped off the blood flow to the right lung, ensuring that it would have to be removed later.

A CT scan showed the bullet’s path through Griego’s chest. It had punctured his right chest near his back and then ricocheted off his spine — somehow not injuring it — and out the top of his left neck.

“He did have injuries to both his lungs,” Elster said. “But this was kind of a lucky shot, in that he did not have any other injuries to his spinal cord or esophagus that would have magnified it.”

The next morning surgeons removed Griego’s right lung, a procedure rarely attempted downrange. They also called Landstuhl Regional Medical Center’s Lung Rescue Team, which flies to combat zones and retrieves servicemembers with serious lung injuries.

The lung team landed in Kandahar that afternoon and tried several different ventilators on Griego, attempting to force air into his remaining lung to make him stable for flight. But all the ventilators failed, and Dr. (Lt. Col.) Sandra Wanek, who led the combat evacuation mission, chose to use a portable heart-lung machine that performs a therapy called extracorporeal membrane oxygenation, or ECMO.

The device, about the size of a suitcase, forces the blood through an artificial membrane that lets in oxygen while taking out carbon dioxide — mimicking the trade-off that naturally takes place in the lungs. The machine worked even better than Wanek expected, and by the time the team landed at Landstuhl several hours later on Oct. 20, Griego’s condition had started to improve.

He was then flown to the university hospital in Regensburg, Germany, where doctors have particular expertise with the portable ECMO machine. Doctors there had also trained Wanek and her team how to use the device in July.

Developed in the 1980s as a way to save the lives of premature infants with underdeveloped lungs, ECMO was never formally approved as a therapy in the United States because the machine was used only as a last-ditch, life-prolonging measure. Recently, however, ECMO machines have been used to treat patients with lung failure, including H1N1 influenza patients, with better prognoses.

Maquet, the company that developed the portable ECMO machine, is trying to get it approved for broader use in the U.S., particularly with patients suffering lung or heart failure who need to be transported.

A ruling by the U.S. Food and Drug Administration is expected sometime next year, but Wanek said she knows what would have happened to Griego had he received same gunshot wound stateside.

“This happens to you in Los Angeles,” she said, “ and the mortality rate is about 70 percent.”

A ventilator, Wanek explained, pushes air into the lungs, but that process can further injure, or even kill, patients whose lungs are damaged and weak.

The ECMO machine bypasses the lungs entirely. At the Regensburg hospital, Griego was kept sedated as the machine controlled the oxygen and carbon dioxide in his bloodstream. His remaining lung was left to heal.

There, Peter Griego read to his son from several hunting magazines, telling him about the latest rifles and archery bows — unsure whether they would again go hunting for deer and elk in mountains a few hours from their home in Mesa, Ariz. A weak squeeze of the hand was the only indication that his son could hear him. But Griego’s remaining lung slowly recovered, and doctors started forcing it to take “baby breaths,” Wanek said.

“As the lung was doing better,” she said, “we were able to let the lung do a little more, and the machine do a little less.”

After more than two weeks at the Regensburg hospital, Griego was taken off the ECMO machine. He returned to Landstuhl, where his tracheotomy tube was also removed, allowing him to talk in whispers when his father held two fingers over his open windpipe.

In Landstuhl’s intensive care unit, Griego sat up for the first time Nov. 8. His 17-year-old brother, Peter Jr., placed headphones on his ears, letting him listen to a favorite ’90s hip-hop group, Atmosphere. Griego’s lips mouthed the words of the songs, and Griego squeezed his younger brother’s hand when he wanted the tune changed.

Wanek said she expected Griego to make a full recovery, “in that he will go home and live a normal life. He just needs to get used to having a lot less lung.”

Griego was eventually flown to Brooke Army Medical Center in San Antonio, where he began physical therapy. He regained the ability to speak on his own last week, and this week he will join his family at the Fisher House to eat turkey and celebrate Thanksgiving.

“It’s my favorite holiday because all of my family is there,” he said. “This time it’s going to be my immediate family and the wounded soldiers and their families. But I definitely think this Thanksgiving will mean the most to me.”

Afterward, his recovery will continue. His legs are weak, but he has started to walk with the help of a family member or a walker.

“I still get winded just sitting up. I yawn like a baby, and when I need to take a deep breath I can tell that it’s not all there,” he said of his missing lung.

None of the doctors have been able to tell Griego precisely what physical limitations he can expect, beyond acknowledging that he will likely not run a marathon anytime soon.

“I think everybody is still amazed that I made it,” he said. “And they are just as curious as me.”

The only family member still unaware of Griego’s injuries and miraculous recovery is his 4-year-old daughter, Rylie.

“I haven’t called her because I’m not sure what I want to tell her,” he said. “But her mother told me she says a prayer for her daddy and his Army buddies every night.”

robbinss@estripes.osd.mil
see more at
http://www.stripes.com/family-thankful-for-medical-innovation-and-for-a-soldier-s-survival-1.126242?localLinksEnabled=false

Monday, December 6, 2010

iLA Membrane Ventilator is the first artificial lung ....

iLA Membrane Ventilator

Hohlfasermembran
A special hollow-fiber membrane assumes the function of pulmonary alveoli.

PaCO2_pH
Effective and reliable: the iLA Membrane Ventilator® (Source: Novalung Support Registry 2008)

The iLA Membrane Ventilator® is the first artificial lung that breathes for the patient outside the body. It removes carbon dioxide outside of the lung, and is perfused by the heart like a natural organ. This relieves the patient’s lung by providing gas exchange support and reducing the workload for the breathing pump. The lung is given “Time to Heal“®.
The iLA Membrane Ventilator® is sometimes referred to in scientific articles as “pecla“ (pumpless extracorporeal lung assist) or ”AVCO2R“ (arterio-venous CO2 removal).

iLA Membranventilator Gas exchange via artificial alveoles

A hollow-fiber membrane is responsible for gas exchange in the artificial lung, which measures only 14 by 14 cm, supporting or even replacing mechanical ventilation. The iLA Membrane Ventilator® is connected to the patient via two NovaPort® femoral cannulas in an arterio-venous circuit. The absence of a mechanical blood pump reduces the risk of inflammatory reactions.

How it works: effective and reliable

The iLA Membrane Ventilator® incorporates a heparin-coated hollow-fiber diffusion membrane and removes carbon dioxide effectively and reliably in a very short period of time to achieve the desired target, using low blood flows of approx. 1 L/min. This extrapulmonary ventilation can be controlled via the sweep gas flow. In cases of respiratory acidosis the pH is generally returned to normal physiological levels within a few hours. This can help protect the kidney and other organs and prevent multi-organ failure.

Easy to use and easy to care for

Positioning therapy and initial mobilization are possible with the iLA Membrane Ventilator thanks to the 360° rotating curve connectors. It is also been used for both inter-hospital and intra-hospital transport. The iLA Membrane Ventilator® was developed for temporary use in intensive-care patients and is approved in Europe for up to 29 days.








click to see more info on this artifical lung by Novalung


Saturday, December 4, 2010

Persistence of tungsten oxide particle/fiber mixtures in artificial human lung fluids

Persistence of tungsten oxide particle/fiber mixtures in artificial human lung fluids

During the manufacture of tungsten metal for non-sag wire, tungsten oxide powders are produced as intermediates and can be in the form of tungsten trioxide (WO3) or tungsten blue oxides (TBOs). TBOs contain fiber-shaped tungsten sub-oxide particles of respirable or thoracic size.

The aim of this research was to investigate whether fiber-containing TBOs had prolonged biodurability in artificial lung fluids compared to tungsten metal or WO3 and therefore potentially could pose a greater inhalation hazard.

Methods: Dissolution of tungsten metal, WO3, one fiber-free TBO (WO2.98), and three fiber-containing TBO (WO2.81, WO2.66, and WO2.51) powders were measured for the materials as-received, dispersed, and mixed with metallic cobalt. Solubility was evaluated using artificial airway epithelial lining fluid (SUF) and macrophage phagolysosomal simulant fluid (PSF).

see  more at
http://7thspace.com/headlines/365713/persistence_of_tungsten_oxide_particlefiber_mixtures_in_artificial_human_lung_fluids.html

Wednesday, November 17, 2010

Vent for Emphysema:A Minimally Invasive Approach to Breathing Easy

Vent for Emphysema: A Minimally Invasive Approach to Breathing Easy

The Emphasys Endobronchial Valve (EBV)
The Emphasys Endobronchial Valve (EBV™) is designed to redirect airflow to healthier lung segments by blocking inhaled air to the diseased portion. Upon exhalation, trapped air is intended to be vented out (as shown in illustration), creating the potential for non-surgical bronchial lung volume reduction.
CREDIT: Courtesy of Emphasys Medical, Inc.™

For patients with emphysema, a lung disease typically caused by cigarette smoking, the fundamental act of breathing becomes a battle. Approximately two million Americans are affected by emphysema, and the vast majority are over age 50. Emphysema occurs when damage to the air sacs affects the elasticity of the lungs, trapping air in the lungs and enlarging the chest wall. In lung volume reduction surgery (LVRS), those parts of the lung most affected by emphysema are surgically removed in order to improve the function of the rest of the lung. After LVRS, patients typically experience less shortness of breath and improved quality of life. In a new clinical trial, the Endobronchial Valve for Emphysema Palliation Trial (VENT), physician-scientists at Columbia are investigating the potential benefits of a less invasive approach to lung reduction.

The VENT trial builds upon the findings of the five-year, multi-center National Emphysema Treatment Trial (NETT), published in The New England Journal of Medicine in May 2003. This landmark study was administered by the National Institutes of Health (NIH) in cooperation with the Centers for Medicare and Medicaid Services (CMS) and was spearheaded at Columbia by Mark E. Ginsburg, MD, Assistant Clinical Professor of Surgery at Columbia University College of Physicians & Surgeons and Surgical Director of The LeBuhn Center for Chest Disease and Respiratory Failure at NewYork-Presbyterian Hospital/ Columbia University Medical Center, along with Byron M. Thomashow, MD, Associate Professor of Clinical Medicine at Columbia and Medical Director of The Courtesy of Emphasys Medical, Inc.™ LeBuhn Center for Chest Disease and Respiratory Failure.

The objective of the NETT was to compare the best medical treatments available with LVRS in patients with severe emphysema. The study demonstrated that in select patients, LVRS significantly reduced both shortness of breath and mortality as compared to medical management alone. As a result of the NETT, the CMS approved coverage for bilateral LVRS in designated centers of excellence, such as Columbia.

Dr. Ginsburg and his co-investigator of the VENT trial, Roger A. Maxfield, MD, Associate Clinical Professor of Medicine at Columbia University College of Physicians & Surgeons, are now hoping to dig a bit deeper into LVRS and reveal the benefits of the new minimally invasive approach. "With the VENT study, we're testing if the Emphasys Endobronchial Valve (EBV™) procedure can be performed effectively through an airway. The EBV™ is an implantable device—it's essentially a one-way valve designed to allow trapped air to vent from the isolated lung segment during exhalation while preventing air inflow during inhalation," explains Dr. Ginsburg.

The Emphasys Endobronchial Valve (EBV™) is designed to redirect airflow to healthier lung segments by blocking inhaled air to the diseased portion. Upon exhalation, trapped air is intended to be vented out (as shown in illustration), creating the potential for non-surgical bronchial lung volume reduction.
"Right now lung reduction surgery is done as an open-chest operation, and it has fairly significant morbidity associated with it," he continues. "If we could take away the trauma of the procedure, we would gain a lot in terms of patient outcomes. The minimally invasive procedure could provide a much faster recovery time; the hope is that patients will stay in the hospital for less than 48 hours—versus an average stay of 9-10 days after open lung reduction. It would also be a less costly procedure."

VENT is a multi-center, randomized, prospective clinical trial designed to primarily study the safety and effectiveness of the EBV™ procedure. Of the 20 centers participating in the trial, Columbia is the only center based in the tri-state area. To be eligible for the trial, patients must have severe emphysema, with the worst damage prevalent in the upper lungs. All patients will be required to undergo pulmonary rehabilitation before and after surgery, and patients will be followed for 18 months after randomization.
"If our outcomes prove as promising as I suspect, then this would be another step forward beyond the NETT—and a major advancement for treating patients with severe emphysema," adds Dr. Ginsburg.

For more information about the VENT trial (IRB# AAAA0812), please contact Dr. Ginsburg at 212.305.1158.

An engineered lung worked when implanted into a rat

An engineered lung worked when implanted into a rat.

Ker Than for National Geographic News Published June 2010

For the first time scientists have reconstructed working lungs in the lab and transplanted them into a living animal.

The achievement is a breakthrough in biomedical engineering that could lead to replacement lungs for humans in the near future, experts say.

Currently, the only way to replace diseased lungs in adults is a lung transplant, a high-risk procedure that's vulnerable to tissue rejection.

In a new study, researchers took lungs from a living rat and used detergents to remove lung cells and blood vessels, revealing the organ's underlying matrix.

This lung "skeleton"—made of flexible proteins, sugars, and other chemicals—consists of a branching network that divides more than 20 times into smaller and smaller structures. (See an interactive graphic of lung structure.)

The researchers placed these "decellularized" lungs into a bioreactor, a machine filled with a slurry containing different types of lung cells extracted from rat fetuses.

(Related: "Scientists Grow Lung Cells From Stem Cells.")

Within several days, the fetal cells naturally attached to the lung matrix and formed a functional lung.

"By and large, the correct subsets of cells went to their correct anatomical locations," explained study leader Laura Niklason, a biomedical engineer at Yale University. "It appears that the lung matrix has cues, or 'zip codes,' that tell the cells where to land."

When the team implanted the engineered lungs into an adult rat for short periods of time—between 45 minutes and two hours—the lungs exchanged oxygen and carbon dioxide in the same way as natural lungs.

"Leap Forward"
By using a natural lung matrix, Niklason's team has avoided one of the biggest hurdles of lung-regeneration attempts—finding a suitable "scaffold" for lung cells to attach to.

Because manufacturing techniques cannot yet replicate nature's complex design, attempts to create synthetic scaffolds have been unsuccessful.

Niklason spent several years trying to create a synthetic lung scaffold, but in the end concluded it was too difficult.

"I decided I couldn't do it, and probably nobody else could either," she said.

The new research represents a "real leap forward" in lung regeneration, said Peter Lelkes, a biomedical engineer at Drexel University in Philadelphia.

"People have engineered organs such as bone and cartilage before, but by comparison to the lung, these are all kids' games," added Lelkes, who was not involved with the study.

Stem Cell Hurdle
Niklason estimates it will be about 20 to 25 years before her team's technique can be used in humans.
That's because a few technical and scientific challenges remain.

Chief among these is finding ways of creating stem cells—which can transform into any other type of cell—from patients with lung disease. No techniques currently exist for creating such cells, which would carry no risk of immune rejection.

(Related: "Liposuction Fat Turned Into Stem Cells, Study Says.")

"The stem cell issue," Niklason said, "is really the big fundamental scientific hurdle."

The research is detailed in this week's issue of the journal Science.




Image courtesy Science/AAAS

Sunday, November 7, 2010

Artificial Lung Closer to Clinical Trial ?

Artificial Lung Closer to Clinical Trial


Clinical Trials
After nearly a decade at the drawing board, "We are looking at what we consider final design changes," Merz says. Clinical trials may get under way in one to two years. The National Institutes of Health recently granted Bartlett $4.8 million to continue the research.

Early animal studies have been promising. In the latest study, University of Texas researcher Joseph Zwischenberger, MD, tried out the BioLung on sheep whose lungs had been badly burned by inhaling smoke. Six of the eight sheep on the BioLung survived five days, whereas only one of six sheep on an external breathing machine survived that long.

Meanwhile, Bartlett has been testing the waters for future human trials. "What we wanted to do was see what the transplantation centers were thinking," he says. So he sent them a survey.

Thirty-one transplant centers completed the survey -- and those were responsible for 72% of all lung transplants in the United States in 1999. Most said they would like to see the BioLung studied in fewer than 25 animals for 30 days before beginning to test the device on humans. Almost all of them said they would support and participate in a clinical trial.

"The FDA would have the final word," Bartlett says. "This is just a start."

A one-month study on two dozen animals may seem hasty, but the situation is dire. Last year, 1,054 people received lung transplants, but 477 died on the waiting list. As of August this year, 3,797 people were still waiting to be matched to a donor.

Most of the transplant centers that responded to Bartlett's survey said the device should be tested first on people with idiopathic (meaning "of unknown cause") pulmonary fibrosis. Among the sickest of these patients, few survive longer than three months.

see more info at
http://www.webmd.com/lung/features/artificial-lung-closer-to-clinical-trial?page=2

Friday, November 5, 2010

Doctors are currently experimenting with artificial lungs

So just how close are we to being able to create a bionic person?



LUNGS
Doctors are currently experimenting with artificial lungs as a way to give patients waiting for a donated lung an increased chance of survival.

One such device is the BioLung, a machine which is roughly the size of a drinks can that is implanted in the chest. The device is packed with hollow plastic fibres perforated with holes so tiny that only gas molecules can pass through them.

As blood filters through the fibres, carbon dioxide escapes through the holes and is replaced by oxygen from the surrounding air.

Researchers claim it can reproduce 100 per cent of normal lung function. Clinical trials are expected to be under way in the next few years.

BIONIC HAND
Not dissimilar to Will Smith's arm in the film I, Robot, in 2007 there was a bionic revolution close to home when Livingston-based company Touch Bionics introduced the first commercially available bionic hand.

LEG
Earlier this year a biotech company in New Zealand revealed that it had created a pair of robotic legs which had helped a man walk again.

The device is not an implant, but rather a robotic exoskeleton, or Rex - a pair of robotic legs that support and assist a person who usually uses a wheelchair. Users strap themselves in and control their movements using a joystick and control pad.

see more om medical progress and lung

Monday, October 25, 2010

Lung taste receptors may help treat asthma

Lung taste receptors may help treat asthma


London: Human lungs can detect bitter tastes the same way as the tongue can, potentially paving the way to new treatments for asthma.

The team from the University of Maryland School of Medicine, US, found that contrary to what they thought, the airways in the lungs opened in response to a bitter taste.

Senior study author Stephen Liggett said: "I initially thought the bitter-taste receptors in the lungs would prompt a 'fight or flight' response to a noxious inhaleant causing chest tightness and coughing so you would leave the toxic environment, but that's not what we found," reports a newspaper.


"It turns out that the bitter compounds worked the opposite way from what we thought," according to the journal Nature Medicine.

"They all opened the airway more profoundly than any known drug that we have for treatment of asthma or chronic obstructive pulmonary disease."

"This could replace or enhance what is now in use and represents a completely new approach," said Liggett.

The team tested bitter substances on human and mouse airways. Quinine and chloroquinine, normally used to combat malaria, were used as they taste bitter along with the artificial sweetner saccharin, which has a bitter aftertaste.


Liggett said: "Based on our research we think that the best drugs would be chemical modifications of bitter compounds which would be aerosolised and then inhaled into the lungs in an inhaler."

The discovery was made by accident when the team were studying muscle receptors that cause contraction and relaxation in the lungs.

It is thought that the bitter substances affect how calcium controls muscles.

Saturday, October 23, 2010

U.S. medical team uses new method to save soldier's life

A breath of life: U.S. medical team uses new method to save soldier's life

LANDSTUHL, Germany -- A U.S. team for the first time in a combat evacuation has used an innovative and portable heart-lung machine, saving a 22-year-old soldier wounded in Afghanistan.
The soldier had been shot in the chest, and a bullet had shredded his lungs.
That’s when Dr. (Lt. Col.) Sandra Wanek got the call. The trauma surgeon led this week’s medevac mission out of Afghanistan as part of Landstuhl Regional Medical Center’s Lung Rescue Team, which flies to combat zones to treat servicemembers with the most serious lung injuries and evacuate them to Germany.

Within hours, Wanek and her team were bound for Kandahar.
When they got there Wednesday, they operated on him for five hours and tried several different ventilators, but all of them failed.
“I just could not improve his oxygenation to the point where it was safe to fly,” Wanek said.
After missing an evacuation flight and doing one more hour of surgery, Wanek chose to use the device — known as an extracorporeal membrane oxygenation (ECMO) machine — for the first time.
The machine, developed in Germany, forces the patient’s blood through an artificial membrane that lets oxygen in and takes carbon dioxide out.
 
 “It takes the place of your lungs,” Wanek said Thursday in the intensive care unit at Landstuhl, where the soldier was being treated. “We are removing all the CO2 from his body and giving him all the oxygen he needs. I don’t have to count on his lungs to do anything.”
Without it, she said, the soldier would likely have died.
The flight out of Afghanistan on Wednesday was the first time the machine, not much bigger than a suitcase, was used while transporting a patient out of a combat zone.
“This is the most exciting thing I’ve ever done in the Army,” Wanek said, looking at her unconscious patient. “It’s the most desperate feeling in the world to have someone who is young and whose wounds are survivable and know that I have nothing I can do for him. But now I do. And it’s small enough; it’s transportable; and it’s safe.”

The soldier, whose name was not released, was flown Thursday from Landstuhl to the university hospital in Regensburg, Germany, where the heart-lung machine was first developed and where doctors have particular expertise with it. It’s also where German doctors trained Wanek and her team on how to use the ECMO, before it was brought to Afghanistan. “We trained in July, and this is the first person who needed it,” she said.

Extracorporeal membrane oxygenation was developed in the 1980s as a way to save the lives of premature infants with underdeveloped lungs. Later, doctors began to use the machines on adults with lung failure, most recently with H1N1 influenza patients.

The early machines, however, were too big and heavy — more than 200 pounds — to be used in transit, such as from an accident scene, so a lighter and more compact device was developed.
In 2006, Regensburg doctors started taking the compact machines on rescue flights and ambulances to treat patients with severe lung injuries, such as from gunshot wounds or stabbings, or acute respiratory illness. They have transported about 70 patients hooked up to the machines.
Unlike a ventilator, which pushes air into the lungs, the ECMO machine bypasses the lungs entirely. The machine, which costs about $300,000, has the approval of the U.S. Food and Drug Administration, though it’s not used stateside to treat patients in transit, Wanek said.

The machine connects to blood vessels in two places: the groin and the jugular vein. Wanek recalled how nervous she was in Afghanistan when she had to unclamp the veins and let the soldier’s blood flow through the tubes.

“I had not felt my heart beat that hard in a long time,” she said.
The machine worked even better than she expected, and by the time the team landed at Landstuhl several hours later, the soldier’s condition had started to improve, said Air Force Maj. Clayne Benson, another anesthesiologist on the lung rescue team.

Dr. Alois Philipp — one of the developers of the machine — accompanied the soldier back to the Regensberg hospital. Philipp will care for the soldier until his lung injuries heal and he is healthy enough to return to Landstuhl. When the soldier does return, Wanek hopes to hand the young man a scrapbook of photos so that he can see all that was done to keep him alive.
“He’s a history-making soldier,” she said, “and he doesn’t know it yet.”

Monday, October 18, 2010

RePneu Lung Volume Reduction Coil (LVRC) System

PneumRx, Inc. Announces CE Mark Approval For Its RePneu® Lung Volume Reduction Coil (LVRC™) System

(www.pneumrx.com ), a medical device company dedicated to bringing innovation and improvements to the treatment of lung disease, today announced that it has received CE Mark approval for its RePneu Lung Volume Reduction Coil (LVRC) System to treat the later stages of emphysema.
The RePneu LVRC System is a minimally invasive device intended to improve lung function in emphysema patients by brochoscopically implanting Nitinol coils into the lungs to compress damaged tissue (lung volume reduction) and restore elastic recoil to the healthier lung tissue. This treatment offers a minimally invasive alternative to lung volume reduction surgery, and works independently of collateral ventilation.

The CE mark approval enables PneumRx to move forward with commercialization in Europe and other select markets. PneumRx intends to launch its RePneu LVRC System in Europe in the last quarter of 2010. PneumRx plans to continue its ongoing partnership with physicians through training and by offering novel products for the diagnosis and treatment of lung disease.

"We are thrilled to have achieved this important milestone, and look forward to introducing our RePneu LVRC to the European market to help improve the lives of so many people who are suffering from emphysema and have few other viable treatment options," said Erin McGurk, President and CEO of PneumRx, Inc. "We are extremely pleased with the significant improvements in pulmonary function tests, exercise tolerance, and quality of life experienced by our clinical trial patients, and expect to bring these same benefits to a broader population of emphysema patients with the commercialization of the RePneu LVRC System in Europe."

About PneumRx, Inc.
PneumRx, Inc. is a rapidly growing medical device company focused on the development and commercialization of innovative products to treat emphysema using minimally-invasive techniques. It is a privately held company located in Mountain View, California.
SOURCE PneumRx, Inc.

Saturday, October 16, 2010

How much does a pack of cigarettes really cost?

How much does a pack of cigarettes really cost? $16.43


On Thursday, Oct. 14, the American Lung Association of Florida will host the first Florida Tobacco Cessation Summit at Lake Nona — a free, one-day event that will examine the benefits of smoking cessation for Floridians.

Participants representing a broad range of industries will learn about the short- and long-term positive outcomes that can result from providing comprehensive cessation coverage.

“Each year I see the devastating health effects of tobacco use throughout Florida,” said Martha Bogdan, president of the American Lung Association of the Southeast. “We have made great strides in reducing tobacco use through smoke-free air laws, increasing the cost of cigarettes and funding tobacco prevention programs. Now it’s time to help those who want to quit smoking succeed by ensuring full access to cessation products and services.”

The event will be held at the Sanford-Burnham Medical Research Institute at Lake Nona. Registration for the event begins at 8 a.m. Although there is no charge to attend, space is limited. For more information on the Florida tobacco summit, click here.

A recent report released by the American Lung Association, Smoking Cessation: the Economic Benefits, revealed startling numbers related to the true costs of tobacco use in Florida. Smoking can be linked to productivity losses of $4.4 billion, premature death losses of $7.9 billion and direct medical expenditures of $7.2 billion – totaling $19.6 billion in loss to the state.

When researchers considered productivity losses and the cost of health-care for smokers, the true cost of a pack of cigarettes in Florida is $16.43.

Tobacco cessation programs have consistently proven effective and the benefits of these programs greatly outweigh the cost of implementing them. Smoking cessation is one of the most cost-effective wellness initiatives employers can undertake, the lung association says.

The summit will feature discussions on tobacco’s impact on smokers, employers and Florida, the benefits of providing smoking cessation treatment, and the recent health care reform and what it means for tobacco addiction treatment in Florida.

see more info at........
http://blogs.orlandosentinel.com/health/2010/10/12/how-much-does-a-pack-of-cigarettes-really-cost-16-43/

Thursday, October 14, 2010

ALung Technologies Closes on $14 Million Financing

ALung Technologies Closes on $14 Million Series A Financing
Developer of Innovative Respiratory Support Device Announces Financing to Support Clinical Trials and Product Commercialization.


PITTSBURGH--(BUSINESS WIRE)--ALung Technologies, Inc. today announced that the Company has closed a $14 Million Series A financing round. The investment will support ongoing clinical trials of the Hemolung™ Respiratory Assist System and its subsequent commercialization. The Company’s Hemolung device is expected to help many patients with acute respiratory failure to avoid intubation and invasive mechanical ventilation.
“We are very excited about the early results coming out of our clinical trial in Germany”
The Hemolung Respiratory Assist System is designed to remove carbon dioxide and deliver oxygen directly to the patient's blood via a small catheter, inserted into the jugular or femoral vein, similar to acute kidney dialysis. This treatment is expected to provide a significant benefit over intubation and mechanical ventilation, in that it will allow the patient to talk and eat, and avoid sedation, while giving the lungs the opportunity to heal.
“This financing will allow ALung to complete its clinical trial in Germany and subsequently commercialize the Hemolung System,” said Peter DeComo, Chairman and CEO of ALung. “The ability of the Company to secure this financing in the current economic climate reinforces the potential of the Hemolung technology to help patients heal more quickly while reducing the overall cost of healthcare.”
A pilot study of the device is currently underway in Germany to demonstrate the safety and performance of the device. A US-based pivotal trial to gain FDA clearance will follow. “We are very excited about the early results coming out of our clinical trial in Germany,” said Nicholas Kuhn, Chief Operating Officer at ALung. “We look forward to completing our clinical trial and introducing the Hemolung to physicians and patients in the near future.”
Eagle Ventures, Inc., a Pittsburgh-based private equity firm, led the financing. Participating in the round were Birchmere Ventures, a Pittsburgh-based early-stage venture capital firm, as well as new and existing individual investors.
ALung Technologies, Inc. is a Pittsburgh-based medical device company commercializing artificial lung devices for the treatment of respiratory failure. The Company’s Hemolung™ Respiratory Assist System is designed to replace or supplement the use of invasive ventilators for patients with acute respiratory failure. For more information about ALung and the Hemolung Respiratory Assist System, please visit http://www.alung.com.

Contacts

ALung Technologies
Scott Morley, +1 412-697-3370
Vice President of Marketingsmorley@alung.com

Monday, October 11, 2010

creating artificial alveolus

This ersatz lung, no bigger than a multivitamin, could represent a new pharmaceutical testing method.

On it, researchers have created an artificial alveolus, one of the sacs in the lungs where oxygen crosses a membrane to enter the body's blood vessels. A polymer sheet that stands in for the membrane is in the blue strip. On one side of the sheet, blood-vessel cells mimic a capillary wall; on the other, lung-cancer cells mimic lung epithelial cells.

Scientists have tested the chip's immune response, and it behaves just like real tissue would, a first step to having lifelike organ systems on which drugs can act. The chip's primary developer, biomedical engineer Dongeun (Dan) Huh of Harvard University, hopes that within two years, the chip will succeed in mimicking the process by which the lungs swap oxygen for carbon dioxide. Huh would like to create a suite of artificial organs to be used in cosmetics testing and pharmaceutical safety trials.

Generating artificial alveolus sounds like a first in building a complete replacement lung.

artificial alveolus,lung replacement

This post by Victor Zapana originally appeared at Popular Science.



Sunday, October 10, 2010

Making a Lung Replacement

Making a Lung Replacement

National Institutes of Health Research Matters

Hot on the heels of progress toward a liver transplant substitute, researchers have made transplantable lung grafts for rats. The accomplishment could pave the way for the development of an engineered human lung.

Lungs have a limited ability to regenerate. The primary therapy for severely damaged lungs is currently lung transplantation—surgery to remove the lung and replace it with a healthy lung from a deceased donor. However, lung transplants are limited by the small number of donor organs available—not much more than 1,000 per year.

To be successful, an artificial lung would need to retain the complex branching geometry of the lung’s airways. It would also require a large network of small blood vessels to transport oxygen and nutrients throughout the structure. Decellularization—the process of removing cells from a structure but leaving a scaffold with the architecture of the original tissue—has shown some success in other organs, including heart and liver. A team of researchers led by Dr. Laura Niklason of Yale University set out to build on this recent progress and develop a similar approach for lungs. Their work was supported by NIH’s National Heart, Lung and Blood Institute (NHLBI) and National Institute of General Medical Sciences (NIGMS).

The researchers harvested lungs from adult rats. Treating the lungs with a mild detergent solution for 2 to 3 hours removed the cells but left the lung architecture intact, as reported in the early online edition of Science on June 24, 2010. A careful analysis showed that a matrix of proteins remained behind to hold the lung’s shape.

To see if they could repopulate the matrix with cells and engineer a functional lung, the researchers injected endothelial cells into the blood vessels and epithelial cells into airways. They kept the matrix for up to 8 days in a novel bioreactor that was designed to mimic the pressure changes and ventilation a lung would experience. The researchers found that the cells reseeded the surfaces of the matrix in their appropriate locations. This finding suggests that the decellularized matrix maintains cues for the cells to attach and thrive.

The researchers tested the engineered lungs in rats for short time intervals (45-120 min) and found that the lungs inflated with air, with only some modest bleeding into airways. Most importantly, the lungs successfully exchanged oxygen and carbon dioxide like natural lungs.

To see whether their method might apply to human tissues, the researchers got human lung segments from a tissue bank. They were able to decellularize the tissues while preserving their architecture. They then reseeded the matrices with epithelial and endothelial cells and found that they adhered at their appropriate locations. This result supports the idea that the approach holds promise for human lung tissue.

“We succeeded in engineering an implantable lung in our rat model that could efficiently exchange oxygen and carbon dioxide, and could oxygenate hemoglobin in the blood. This is an early step in the regeneration of entire lungs for larger animals and, eventually, for humans,” says Niklason. She notes that years of research with adult stem cells will likely be needed to develop ways to repopulate lung matrices and produce fully functional lungs for people.

—by Harrison Wein, Ph.D.

Related Links:
Lung Transplant:

http://www.nhlbi.nih.gov/health/dci/Diseases/lungtxp/lungtxp_whatis.html

click to see more info news on lung transplants and Lung Replacements

ALung Technologies raises $14M

ALung Technologies raises $14M from angel investors

Pittsburgh Business Times - by Malia Spencer and Patty Tascarella

Joe Wojcik
Eagle Ventures President Mel Pirchesky, left, and ALung Technologies Chairman and CEO Pete DeComo stand with a Hemolung, an artificial lung designed to be used in an intensive care unit.
View Larger ALung Technologies Inc. has raised $14 million in its biggest capital round to date, almost all from 90 individual investors who are either active or retired entrepreneurs and chief executives.

The South Side-based respiratory support company has earmarked the money for general operations, including finalizing European clinical trials of its artificial lung, starting tests in the United States, and moving to larger space, said CEO Pete DeComo.

ALung already has added four key positions this year — a vice president of operations and manufacturing, and directors of clinical affairs, finance and manufacturing — and the company, which has outgrown its 6,000-square-foot office in the Terminal Building, is set to move to a 15,000-square-foot location at 25th and Jane streets on the South Side by year-end. The larger space will allow for the expansion of the development and manufacturing areas of the business as the company moves toward commercialization of its Hemolung System.

The Hemolung System, which consists of a console and artificial lung, is designed to treat patients with chronic obstructive pulmonary disease. Blood is removed through a catheter and fed through an artificial lung, where the carbon dioxide is exchanged with oxygen before traveling back into the body. Unlike traditional treatment with mechanical ventilators, Hemolung patients can remain alert during treatment and, in some cases, are ambulatory.

Each console costs roughly $25,000. The artificial lung, tubing and catheter run about $6,000 for a seven-day supply. The company can build four systems a week, but that is expected to increase at the new site.

ALung’s clinical trials in Germany are expected to conclude in early 2011, paving a path for the company to sell its medical device in Europe. ALung also expects to submit its paperwork with the U.S. Food and Drug Administration to begin clinical trials in the U.S. by mid-2011, DeComo said.

DeComo, who started his career as a respiratory therapist at UPMC, said ALung’s product treats conditions familiar to almost everyone.

“You can envision a friend or relative in the ICU,” he said. “That’s also helped with the funding.”

FUNDRAISING THROUGH ANGELS
To get to $14 million before clinical trials were complete, ALung took a nontraditional fundraising route that has been growing in popularity during the post-recession era.

DeComo first met with several venture capital firms — including some who staked his previous company, Renal Solutions, which sold in 2007 for $200 million to Germany-based Fresenius Medical Care — but got the same response.

“They all said, ‘Come back when you have human data,’” he said.

Since ALung was too early-stage for venture capitalists, DeComo decided instead to approach angel investors, and met with Mel Pirchesky, CEO of Oakland-based Eagle Ventures, to set up meetings between ALung and wealthy individuals.

Fundraising began in fall 2009, soon after ALung brought in $2.5 million from its existing investors, DeComo said.

Although it took 10 months, the South Side-based respiratory support company raised far more than its initial goal.

“Actually, we originally were looking for $6 million,” DeComo said. “Then we took it up to $8 million, then $10 million, and finally $14 million.”

The recession had an impact.

“Half the people I called got hurt by the stock market and had no liquidity,” Pirchesky said. “But the other half had cash and were looking to put their money in other places than the stock market.”

The price to invest was $250,000. Some angels banded together, forming limited liability partnerships, so 90 individuals translated into 50 shareholders at a total of $13.5 million. The final $500,000 came from a venture capital firm, North Side-based Birchmere Ventures. Birchmere partner Gary Glausser was not immediately available to comment.

Neither DeComo nor Pirchesky would identify the angels, except to say that they, and ALung COO Nicholas Kuhn, are among them. Pirchesky said two-thirds are Pittsburghers, and 90 percent are active or retired CEOs or entrepreneurs. Some are venture capitalists who invested their own money, DeComo said.

Large rounds by groups of independent investors is “absolutely” on the upswing across the country, said John Taylor, National Venture Capital Association research and financial affairs executive.

“The lines between traditional venture capital — from pension funds and endowment money — and angels is blurring,” Taylor said. “The trend is for angels to do larger rounds, but $14 million is fairly sizable and on the higher-end.”

Decomo said the capital should carry ALung through the end of 2011, but expects to launch another capital raise in six months. The amount has not been determined.

Saturday, October 9, 2010

$14 million to fund artificial lung trials: ALung

firm raises $14 million to fund artificial lung trials


A South Side-based medical device company raised $14 million to fund the completion of clinical trials on its artificial lung device-- in use by two patients in Germany -- as a prelude to seeking approval in the United States, the company said Thursday.

ALung Technologies Inc. completed raising the $14 million in preferred stock this week, which should provide the company with financing through January 2012 so that it can complete its pilot trials, CEO Peter DeComo said. The company had raised $16.5 million in private money over the past decade.

Of the $14 million in new funding, $500,000 came from Birchmere Ventures, a venture capital firm that targets early-stage companies, also based on the South Side. The remainder came from 90 individual investors, some of whom are physicians, said Mel Pirchesky, president of Eagle Ventures Inc., a Highland Park-based firm that raised the money. Pirchesky, whose company charged a percentage of the amount of money it raised, said he is among the investors in ALung.

ALung's Hemolung is designed to replace or supplement traditional ventilators used in hospitals. The artificial lung removes carbon dioxide from the blood and replaces it with oxygen, which is pumped into the patient's blood as it circulates through tubes connected to a vein.
DeComo was optimistic that successful use of the artificial lung on the patients in Germany will lead to an approval for use in Europe by mid-2011. The data gathered from the pilot project can be submitted to the Food and Drug Administration, DeComo said. ALung intends to apply to the FDA for permission to conduct a "pivotal trial" test on patients in the United States, he noted.

Approval for use in the European Union will permit ALung to generate revenue while conducting U.S. trials, DeComo said.
"There's no way we can't get through the FDA trials" and win approval to use the artificial lung in the United States, DeComo said.

To see more of The Pittsburgh Tribune-Review or to subscribe to the newspaper, go to http://www.pittsburghlive.com/x/pittsburghtrib/.
By Joe Napsha, The Pittsburgh Tribune-Review Oct.

Saturday, October 2, 2010

Development of Artificial Alveoli

Development of Artificial Alveoli to Study Ventilator-Induced Lung Injury.
Authors: Kamotani, Yoko
Keywords: Lung
Microfluidics
Issue Date: 2008
Abstract: Ventilator-induced lung injury (VILI) is a significant health risk for patients placed on mechanical ventilators when the ventilator settings required to sustain life can instead exacerbate or initiate significant lung injury and inflammation. VILI occurs in 5-15% of mechanically ventilated patients with an associated mortality rate of 34-60% and is characterized by increased pulmonary edema, impairment of the surfactant system, and a massive inflammatory response. VILI manifests itself primarily on the level of the alveolus where the cells of the alveolar epithelium undergo abnormally high cyclic strains during ventilation which can result in structural disruption and cytokine release. The successful development of strategies to suppress the damaging effects of VILI depends on understanding the mechanisms of injury yet the specific causes remain unknown. In vitro methods to study VILI including whole lung models and cell stretching devices are either macroscopic or low throughput. To overcome these limitations of traditional systems and to provide an added degree of physiological relevance is to use microtechnology to recreate aspects of biological environments seen in vivo where microfluidics and other microscale phenomena dominate at the cellular level. This thesis describes 4 microsystems that take advantage of microtechnology and when integrated can form an ‘artificial alveoli’ microchip to study VILI. The first microsystem is a series of individually programmable cell stretching microwell arrays where cell alignment in response to applied cyclic strain can be quantified. In the second, cells cultured in wells can be stretched using an air-liquid interface to show increasing damage to epithelial cells. For an on-chip analysis of the biochemical responses of cells to cytokine exposure, the third device is a self-contained microfluidic immunoassay system where liquid flow is controlled using the pins of a Braille display. The fourth is a multi-width multi-depth microchannel network to generate biomimetic vasculatures. The first two and the fourth microsystems are technical device-oriented projects, while the third is used to probe a unique unexplored biological theory that the structural damage of the alveolar epithelium found in VILI is largely due to the stretching of alveoli using an air-liquid interface during ventilation.



Development of Artificial Alveoli

seee the full article at..........

http://deepblue.lib.umich.edu/handle/2027.42/58536

Living, breathing human lung-on-a-chip

Living, breathing human lung-on-a-chip: A potential drug-testing alternative

Date: Jun 24, 2010
Lung on a chip
The lung on a chip, shown here, was crafted by combining microfabrication techniques from the computer industry with modern tissue engineering techniques, human cells, and a plain old vacuum pump. [Photo credit: Felice Frankel.]
BOSTON, Mass. -- Researchers from the Wyss Institute for Biologically Inspired Engineering at Harvard University, Harvard Medical School, and Children's Hospital Boston have created a device that mimics a living, breathing human lung on a microchip. The device, about the size of a rubber eraser, acts much like a lung in a human body and is made using human lung and blood vessel cells.

Because the lung device is translucent, it provides a window into the inner-workings of the human lung without having to invade a living body. It has the potential to be a valuable tool for testing the effects of environmental toxins, absorption of aerosolized therapeutics, and the safety and efficacy of new drugs. Such a tool may help accelerate pharmaceutical development by reducing the reliance on current models, in which testing a single substance can cost more than $2 million.

"The ability of the lung-on-a-chip device to predict absorption of airborne nanoparticles and mimic the inflammatory response triggered by microbial pathogens provides proof-of-principle for the concept that organs-on-chips could replace many animal studies in the future," says Donald Ingber, senior author on the study and founding director of Harvard's Wyss Institute.

The paper appears in the June 25 issue of Science.

Room to breathe
Until now, tissue-engineered microsystems have been limited either mechanically or biologically, says Ingber, who is also the Judah Folkman professor of vascular Biology at Harvard Medical School and Children's Hospital Boston. "We really can't understand how biology works unless we put it in the physical context of real living cells, tissues, and organs."

With every human breath, air enters the lungs, fills microscopic air sacs called alveoli, and transfers oxygen through a thin, flexible, permeable membrane of lung cells into the bloodstream. It is this membrane -- a three-layered interface of lung cells, a permeable extracellular matrix, and capillary blood vessel cells -- that does the lung's heavy lifting. What's more, this lung-blood interface recognizes invaders such as inhaled bacteria or toxins and activates an immune response.

The lung-on-a-chip microdevice takes a new approach to tissue engineering by placing two layers of living tissues -- the lining of the lung's air sacs and the blood vessels that surround them -- across a porous, flexible boundary. Air is delivered to the lung lining cells, a rich culture medium flows in the capillary channel to mimic blood, and cyclic mechanical stretching mimics breathing.  The device was created using a novel microfabrication strategy that uses clear rubbery materials. The strategy was pioneered by another Wyss core faculty member, George Whitesides, the Woodford L. and Ann A. Flowers University Professor at Harvard University.

"We were inspired by how breathing works in the human lung through the creation of a vacuum that is created when our chest expands, which sucks air into the lung and causes the air sac walls to stretch," says first author Dan Huh, a Wyss technology development fellow at the Institute. "Our use of a vacuum to mimic this in our microengineered system was based on design principles from nature."

To determine how well the device replicates the natural responses of living lungs to stimuli, the researchers tested its response to inhaled living E. coli bacteria. They introduced bacteria into the air channel on the lung side of the device and at the same time flowed white blood cells through the channel on the blood vessel side. The lung cells detected the bacteria and, through the porous membrane, activated the blood vessel cells, which in turn triggered an immune response that ultimately caused the white blood cells to move to the air chamber and destroy the bacteria.

"The ability to recreate realistically both the mechanical and biological sides of the in vivo coin is an exciting innovation," says Rustem Ismagilov, professor of chemistry at the University of Chicago, who specializes in biochemical microfluidic systems.

The team followed this experiment with a "real-world application of the device," says Huh. They introduced a variety of nano-scaled particles (a nanometer is one-billionth of a meter) into the air sac channel. Some of these particles exist in commercial products; others are found in air and water pollution. Several types of these nanoparticles entered the lung cells and caused the cells to overproduce free radicals and to induce inflammation.  Many of the particles passed through the model lung into the blood channel, and the investigators discovered that mechanical breathing greatly enhanced nanoparticle absorption. Benjamin Matthews, Harvard Medical School assistant professor in the Vascular Biology Program at Children's Hospital Boston, verified these new findings in mice.

"Most importantly, we learned from this model that the act of breathing increases nanoparticle absorption and that it also plays an important role in inducing the toxicity of these nanoparticles," Huh says.

Organs-on-chips
"This lung-on-a-chip is neat and merges a number of technologies in an innovative way," says Robert Langer, MIT Institute professor. "I think it should be useful in testing the safety of different substances on the lung and I can also imagine other related applications, such as in research into how the lung functions."

According to Ismagilov, it's too early to predict how successful this field of research will be.  Still, "the potential to use human cells while recapitulating the complex mechanical features and chemical microenvironments of an organ could provide a truly revolutionary paradigm shift in drug discovery," he says.

The investigators have not yet demonstrated the system's capability to mimic gas exchange between the air sac and bloodstream, a key function of the lungs, but, says Huh, they are exploring this now. 

The Wyss Institute team is also working to build other organ models, such as a gut-on-a-chip, as well as bone marrow and even cancer models. Further, they are exploring the potential for combining organ systems.

For example, Ingber is collaborating with Kevin Kit Parker, associate professor at Harvard University's School of Engineering and Applied Sciences and another Wyss core faculty member, who has created a beating heart-on-a-chip. They hope to link the breathing lung-on-a-chip to the beating heart-on-a-chip. The engineered organ combination could be used to test inhaled drugs and to identify new and more effective therapeutics that lack adverse cardiac side effects.

This research was funded by the the National Institutes of Health, the American Heart Association, and the Wyss Institute for Biologically Inspired Engineering at Harvard University.

Written by Elizabeth Dougherty

Contact:
Mary Tolikas
mary.tolikas@wyss.harvard.edu
###
The Wyss Institute for Biologically Inspired Engineering at Harvard University uses Nature's design principles to create breakthrough technologies that will revolutionize medicine, industry, and the environment.  Working as an alliance among Harvard's Medical School, School of Engineering and Applied Sciences, and Faculty of Arts and Sciences, and in partnership with Beth Israel Deaconess Medical Center, Children's Hospital Boston, Dana Farber Cancer Institute, University of Massachusetts Medical School, and Boston University, the Institute crosses disciplinary and institutional barriers to engage in high-risk, fundamental research that leads to transformative change. By applying biological principles, Wyss researchers are developing innovative new engineering solutions for healthcare, manufacturing, robotics, energy, and sustainable architecture. These technologies are translated into commercial products and therapies through collaborations with clinical investigators, corporate alliances and new startups.

Harvard Medical School (http://hms.harvard.edu) has more than 7,500 full-time faculty working in 11 academic departments located at the School's Boston campus or in one of 47 hospital-based clinical departments at 17 Harvard-affiliated teaching hospitals and research institutes. Those affiliates include Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Cambridge Health Alliance, Children's Hospital Boston, Dana-Farber Cancer Institute, Forsyth Institute, Harvard Pilgrim Health Care, Hebrew SeniorLife, Joslin Diabetes Center, Judge Baker Children's Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, McLean Hospital, Mount Auburn Hospital, Schepens Eye Research Institute, Spaulding Rehabilitation Hospital, and VA Boston Healthcare System.

see more info on living breathing human lungs on a chip